Are you a Healthcare Professional?
This section of the AMITIZA website is for healthcare professionals only.
Use these tools to help track your symptoms and how you're doing with AMITIZA, and share the results with your doctor to get the most out of your next appointment.
Learn more about chronic constipation from these organizations to get a more thorough understanding of the condition.
The Digestive Disease National Coalition (DDNC) is an advocacy organization made up of major national voluntary and professional societies that deal with digestive diseases. The DDNC focuses on improving public policy related to digestive diseases and increasing public awareness with respect to diseases of the digestive system.
The Gastro-Intestinal Research Foundation (GIRF) is a non-profit organization dedicated to raising funds for clinical and laboratory research at the University of Chicago Medicine Digestive Diseases Center.
The International Foundation for Functional Gastrointestinal Disorders (IFFGD) Inc. is a nonprofit education and research organization dedicated to informing, assisting, and supporting people affected by gastrointestinal disorders. Founded in 1991, the IFFGD works with patients, families, physicians, nurses, practitioners, investigators, regulators, employers, and others to improve digestive health in adults and children.
The National Digestive Diseases Information Clearinghouse (NDDIC) is an information spreading service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
The NIDDK is part of the National Institutes of Health (NIH), which is part of the U.S. Department of Health and Human Services.
NDDIC was established in 1980 to increase knowledge and understanding about digestive diseases among people with these conditions and their families, health care professionals, and the general public. To carry out this mission, NDDIC works closely with a coordinating panel of representatives from Federal agencies, voluntary organizations on the national level, and professional groups to identify and respond to informational needs about digestive diseases.
AMITIZA is used for 3 types of chronic constipation: CIC in adults, OIC in adults with chronic pain that is not caused by active cancer, and IBS-C in women ≥ 18 years. Effectiveness in patients taking methadone has not been established.
AMITIZA (lubiprostone) is not for everyone. If you know or suspect you have a bowel blockage, do not take AMITIZA. If you are unsure, your healthcare provider (HCP) should evaluate your condition before starting AMITIZA.
Some patients taking AMITIZA may experience nausea. Take AMITIZA with food and water to reduce the occurrence of nausea.
Do not take AMITIZA if you have severe diarrhea. Some patients taking AMITIZA may experience diarrhea. If your diarrhea becomes severe, stop taking AMITIZA and tell your HCP.
Patients may experience fainting and low blood pressure after taking the first dose or repeated doses of AMITIZA. Stop taking AMITIZA and tell your HCP if these reactions occur. Symptoms usually go away before the next dose but may recur with repeated use. Tell your HCP if you are taking any medications to lower blood pressure. Other side effects such as diarrhea or vomiting may increase the risk of fainting and low blood pressure.
Within an hour of taking AMITIZA, a sensation of chest tightness and shortness of breath may occur. These symptoms usually go away within three hours, but may recur with repeated use. Tell your HCP if you experience these symptoms.
The most common side effects of taking AMITIZA 24 mcg twice daily for CIC are nausea, diarrhea, headache, abdominal pain, abdominal distension, and gas. The most common side effects of taking AMITIZA 24 mcg twice daily for Opioid-Induced Constipation are nausea and diarrhea. The most common side effects of taking AMITIZA 8 mcg twice daily for IBS-C are nausea, diarrhea, and abdominal pain. These are not all the side effects associated with AMITIZA.
Tell your HCP if you are taking a diphenylheptane opioid (e.g., methadone).
AMITIZA has not been studied in pregnant women. Based on animal studies, AMITIZA may cause fetal harm. AMITIZA should only be used during pregnancy if the potential benefits justify the potential risk to the fetus. If you are pregnant or become pregnant while being treated with AMITIZA, talk to your HCP to evaluate the risks to the fetus. Tell your HCP if you are nursing and monitor infants for diarrhea.
Tell your HCP if you have liver problems.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
AMITIZA (lubiprostone) 24 mcg capsules twice daily is approved to treat Chronic Idiopathic Constipation (CIC) in adults. “Idiopathic” means the cause of the constipation is unknown and not due to an underlying illness or medication. AMITIZA 24 mcg twice daily is also approved to treat constipation caused by opioids, a type of prescription pain medicine, in adults with chronic pain that is not caused by active cancer. The effectiveness of AMITIZA has not been established if you are taking a diphenylheptane opioid (e.g., methadone). AMITIZA 8 mcg capsules twice daily is approved to treat Irritable Bowel Syndrome with Constipation (IBS-C) in women ≥ 18 years of age.
Please click here for complete Prescribing Information.